Evidence map›Paper›PMID 41918745›Full record

ArticleFrontiers in immunology2026

Subgroups based on autoantibody status associated with clinical manifestations,

Shengfang Bao, Jingyi Lu, Jiani Ma, Yingying Jin, Hua Huang, Zhen Yang, Xuemei Xu, Chenxi Liu, Xiqiong Han, Liping Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shengfang BaoDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jingyi LuDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Jiani MaDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yingying JinDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Hua HuangDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Zhen YangDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xuemei XuDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chenxi LiuDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Xiqiong HanDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Liping WangDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Sun ChenDepartment of Pediatric Cardiology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yufeng LiDepartment of Pediatric Nephrology, Rheumatology and Immunology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Yanliang JinDepartment of Rheumatology and Immunology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Childhood-onset systemic lupus erythematosus (cSLE) exhibits significant heterogeneity, leading to challenges in prognosis and treatment. This study aims to stratify cSLE patients into clinically distinct subgroups based on routine autoantibody profiles and to characterize these subgroups by their differences in Methods: We conducted a retrospective study of 102 cSLE patients. An unsupervised two-step cluster analysis was performed using nine routinely measured autoantibodies. The resulting subgroups were compared for clinical features, Results: Cluster analysis identified two distinct subgroups. Subgroup 2, characterized by anti-Sm/RNP positivity, demonstrated significantly more severe disease, including higher rates of lupus nephritis, neuropsychiatric involvement, and elevated SLE disease activity index (SLEDAI) scores at diagnosis compared to subgroup 1 (anti-Sm/RNP-negative). Genetically, subgroup 2 was enriched with the Conclusion: Autoantibody-based stratification effectively delineates two cSLE subgroups with distinct genetic, immunological, and clinical trajectories. The anti-Sm/RNP positive subgroup, defined by

Indexed as

AutoantibodiesCytokinesHLA-DRB1 ChainsLupus Erythematosus, SystemicVasculitisAdolescentAge of OnsetChildFemaleGene FrequencyGenetic Predisposition to DiseaseHumansMaleRetrospective StudiesAutoantibodiesCytokinesHLA-DRB1 Chainsbelimumabcluster analysiscytokinesHLAinterferon-alphainterleukinlupus

Identifiers

PMID41918745
PMCPMC13033651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.